



**BlueCross
BlueShield**

Federal Employee Program.

TRASTUZUMAB

Herceptin (trastuzumab), Hercessi* (trastuzumab-strf), Herzuma (trastuzumab-pkrb),
Kanjinti (trastuzumab-anns), **Ogivri** (trastuzumab-dkst), **Ontruzant** (trastuzumab-dttb),
Trazimera (trastuzumab-qyyp)

Preferred products: Kanjinti, Ogivri, Ontruzant

*Product covered on the medical benefit only

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or greater

Diagnoses

Patient must have **ONE** of the following:

1. HER2-overexpressing breast cancer
 - a. HER2 protein overexpression or HER2 gene amplification as determined by an FDA-approved test
2. HER2-overexpressing metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
 - a. HER2 protein overexpression or HER2 gene amplification as determined by an FDA-approved test
3. Unresectable or metastatic colorectal cancer
 - a. RAS wild-type, as determined by an FDA-approved test
 - b. HER2-positive
 - c. Cancer has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy
 - d. Used in combination with tucatinib

AND ALL of the following:

- a. Prescriber agrees to monitor for cardiac function and pulmonary toxicity
- b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with trastuzumab and for 7 months after the last dose
- c. **Non-preferred medications only**: Inadequate treatment response, intolerance, or contraindication to **ONE** of the preferred products (Kanjinti, Ogivri, Ontruzant)

Prior - Approval Limits

Duration 12 months



**BlueCross
BlueShield**

Federal Employee Program.

TRASTUZUMAB

Herceptin (trastuzumab), Hercessi* (trastuzumab-strf), Herzuma (trastuzumab-pkrb),
Kanjinti (trastuzumab-anns), **Ogivri** (trastuzumab-dkst), **Ontruzant** (trastuzumab-dttb),
Trazimera (trastuzumab-qyyp)

Preferred products: Kanjinti, Ogivri, Ontruzant

*Product covered on the medical benefit only

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. HER2-overexpressing breast cancer
2. HER2-overexpressing metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
3. Unresectable or metastatic colorectal cancer
 - a. Used in combination with tucatinib

AND ALL of the following:

- a. Prescriber agrees to monitor for cardiac function and pulmonary toxicity
- b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Trastuzumab and for 7 months after the last dose

Prior – Approval *Renewal* Limits

Same as above